Padmaja Chilukoti
Pediatric Endocrinology · Ashtabula, OHNPI 1053704148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 223 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$602
- Lilly USA, LLC$542
- Novo Nordisk$489
- AbbVie$399
- Abbott$374
- Merck$279
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,53799%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 19 | $602 |
| Lilly USA, LLC | 30 | $542 |
| Novo Nordisk | 23 | $489 |
| AbbVie | 21 | $399 |
| Abbott | 20 | $374 |
| Merck | 18 | $279 |
| Amgen | 14 | $248 |
| Xeris Pharmaceuticals, Inc. | 11 | $223 |
| Cequr Corporation | 3 | $157 |
| Amneal Pharmaceuticals LLC | 5 | $119 |
| Neurocrine Biosciences, Inc. | 4 | $111 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| AstraZeneca | 3 | $88 |
| Antares Pharma, Inc. | 4 | $71 |
| Dexcom, Inc. | 4 | $70 |
| Bayer | 4 | $66 |
| Medtronic | 3 | $65 |
| Azurity Pharmaceuticals, Inc. | 4 | $62 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| Biomarin Pharmaceutical Inc. | 2 | $43 |
| GSK | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $39 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Amryt Pharma Holdings Ltd | 2 | $36 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $23 |
| Insulet Corporation | 1 | $19 |
| Pfizer | 1 | $18 |
| RGH Enterprises LLC | 1 | $17 |
| Qiagen, LLC | 1 | $16 |
| Zealand Pharma US, Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$119
How this compares
$4,563 in reported general payments places this provider in the 75th percentile of 76 pediatric endocrinology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 249 | $326,538 |
| MounjaroTirzepatide | 163 | $197,601 |
| JardianceEmpagliflozin | 117 | $155,972 |
| TrulicityDulaglutide | 54 | $61,020 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 262 | $35,428 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 110 | $35,226 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $34,363 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $31,144 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $30,690 |
| RybelsusSemaglutide | 14 | $26,225 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $25,521 |
| FarxigaDapagliflozin Propanediol | 20 | $22,160 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $16,890 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,703 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $15,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $489 | $359,401274 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $542 | $265,000249 claims |
| AstraZenecaFarxiga | $88 | $22,16020 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $119 | $1,421160 claims |
| AbbVieSynthroid | $399 | $49412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 76 pediatric endocrinology providers in Ohio.
Other pediatric endocrinology in Ashtabula
- Philippe BackeljauwCincinnati$632K
- Andrew DauberCincinnati$192K
- Nana Hawa Yayah JonesCincinnati$92K
- Jennifer DyerColumbus$71K
- Sarah MacleishCleveland$19K
- Bradley VansickleAkron$19K
- Susan RoseCincinnati$17K
- Sasigarn BowdenColumbus$16K
- Iris Gutmark-LittleCincinnati$14K
- Kathryn ObrynbaColumbus$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.